Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

This study has been completed.

Sponsor:

Collaborator:

National Institute on Drug Abuse (NIDA)

Information provided by:

University of Vermont

ClinicalTrials.gov Identifier:

NCT00000230

First received: September 20, 1999

Last updated: May 5, 2016

Last verified: August 1996

History of Changes

Purpose

The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase 2


Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Buprenorphine Detoxification With Two Types of Treatment. BBD III

Resource links provided by NLM:

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by University of Vermont:

Primary Outcome Measures:

Drug use
Retention
Weeks abstinent
Weeks continuous abstinence
Overall treatment outcome


Estimated Enrollment:	0
Study Start Date:	January 1995

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000230

Locations


United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401

Sponsors and Collaborators

University of Vermont

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Warren Bickel, Ph.D.	University of Vermont

More Information


ClinicalTrials.gov Identifier:	NCT00000230 History of Changes
Other Study ID Numbers:	NIDA-06969-12 R01DA006969 R01-06969-12
Study First Received:	September 20, 1999
Last Updated:	May 5, 2016
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:


Opioid-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Buprenorphine Analgesics, Opioid Narcotics	Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Narcotic Antagonists

ClinicalTrials.gov processed this record on September 30, 2016

To Top